TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21868190
Drug: Subacromial infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial infiltration of local anesthesia (20 mL of 1% ropivacaine)
Study: 3033444
Drug: CE +
Normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE + cyproterone acetate (CPA) 12.5 mg/day from day 1 to day 10
Study: 3033444
Drug: Tibolone (ORG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (ORG OD14) 2.5 mg/day
Study: 3033444
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one tablet/day
Study: 10797866
Drug: SPE‐712‐1 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPE‐712‐1 oral suspension 300 mg/15 mL
Study: 10797866
Drug: Rotram tablets
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotram tablets 300 mg
Study: 7720912
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized DHEA (50 mg/d)
Study: 2116441
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion started 1 min after TRH (Group A)
Study: 2116441
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion started 10 min after TRH (Group B)
Study: 2116441
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion started 20 min after TRH (Group C)
Study: 31938840
Drug: 4 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cc autologous muscle-derived cell (AMDC) injections
Study: 31938840
Drug: 4 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cc placebo solution injections
Study: 26645209
Drug: Lurasidone (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40-80 mg/d, flexibly dosed)
Study: 25091659
Drug: Pertuzumab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (in combination with trastuzumab and docetaxel)
Study: 16158743
Drug: Kanefron H
Normalized name: oxymetazoline hydrochloride Nasal Spray [Anefrin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanefron H (KH) after initial anti-inflammatory treatment
Study: 16158743
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (spasmolytic and anti-inflammatory therapy)
Study: 12665729
Drug: Computer-assisted instructional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted instructional (CAI) game focusing on reducing environmental irritants/allergens and correct use of prescribed medications for 12 weeks
Study: 10757465
Drug: Imidapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (10 mg) administered in the morning (07:00)
Study: 10757465
Drug: Imidapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (10 mg) administered in the evening (18:00)
Study: 8843225
Drug: Bivalent recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent recombinant baculovirus influenza A vaccine (rHA0)
Study: 8843225
Drug: Monovalent recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent recombinant baculovirus influenza A vaccine (rHA0)
Study: 8843225
Drug: Standard trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trivalent inactivated vaccine (TIV)
Study: 8843225
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of A/Texas rHA0 (15 micrograms)
Study: 8843225
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of A/Texas rHA0 (45 micrograms)
Study: 19953227
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg cortisol
Study: 17876009
Drug: Self-administered stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered stress management training
Study: 12065562
Drug: Professionally administered
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally administered stress management training
Study: 2203243
Drug: Bepridil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (200 mg/day twice daily)
Study: 2203243
Drug: CERM 4205
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERM 4205 (200 mg/day twice daily)
Study: 31093796
Drug: Oral screen
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral screen after MMF
Study: 23269772
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (second cycle)
Study: 7871360
Drug: Miconazole 2%
Normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole 2% gel applied four times daily for 2 weeks
Study: 16906641
Drug: Zataria multiflora
Normalized name: Reynoutria multiflora root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zataria multiflora 0.1% gel applied four times daily for 2 weeks
Study: 10490157
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl (15 microg x kg(‐1))
Study: 10490157
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fentanyl (1 microg x kg(‐1))
Study: 8725888
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy with leuprolide plus flutamide
Study: 1759789
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release verapamil (240 mg/24 h)
Study: 1759789
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg, 50 mg/24 h)
Study: 1759789
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sustained release verapamil + captopril
Study: 26700279
Drug: Multidisciplinary Multistep
Normalized name: MultiStem
DrugBank: MultiStem (DB15742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary Multistep Medication Review (3MR)
Study: 26076022
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride (DH) 5 mg/day
Study: 19574961
Drug: Difference in
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difference in BW before and after treatment between the two groups
Study: 23265686
Drug: Rimonabant (cannabinoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (cannabinoid antagonist)
Study: 16766329
Drug: M. vaccae
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. vaccae vaccine (two subcutaneous injections 3 months apart)
Study: 8486881
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of quinine taken at bedtime
Study: 21365028
Drug: Buccal plate
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal plate preservation (BPP)
Study: 18390891
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Benazepril and Valsartan)
Study: 2015715
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment mentioned)
Study: 11475742
Drug: Nitroglycerin 5
Normalized name: nitroglycerin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 5 mg
Study: 10556002
Drug: PAPU (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAPU (150 mg)
Study: 773198
Drug: Methylprednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (2 gm, approximately 30 mg/kg)
Study: 29268598
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg)
Study: 29666026
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with chemotherapy
Study: 17382027
Drug: Small molecule
Normalized name: Small molecule melanocortin 4 receptor agonist
DrugBank: LB54640 (DB18331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitors targeting VEGF receptor and tyrosine kinase receptor combined with standard chemotherapy
Study: 15126020
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (lemon-flavored cod liver oil and children's multivitamin-mineral with selenium)
Study: 11641299
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and heparin
Study: 11641299
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with intralipid and heparin
Study: 2530998
Drug: mivacurium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.25 mg kg‐1
Study: 444345
Drug: suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.0 mg kg‐1
Study: 7640130
Drug: atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.5 mg kg‐1
Study: 2530998
Drug: mivacurium (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium (higher doses)
Study: 1173736
Drug: Proprietary milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary milk with lactase preparation
Study: 31397943
Drug: bleselumab 50
Normalized name: Bleselumab
DrugBank: Bleselumab (DB15253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleselumab 50 mg
Study: 31397943
Drug: bleselumab 500
Normalized name: Bleselumab
DrugBank: Bleselumab (DB15253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleselumab 500 mg
Study: 29710295
Drug: Fosfomycin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin, single 3-g dose (n=258)
Study: 26316344
Drug: tissue-type plasminogen
Normalized name: Tissue-type plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: tissue-type plasminogen activator plus endovascular therapy (Solitaire device)
Study: 23597719
Drug: RV3-BB rotavirus
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB rotavirus vaccine (8.3×10(6)FFU/mL)
Study: 31392363
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen treatment
Study: 31392363
Drug: Local estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local estrogen treatment (LET)
Study: 10902991
Drug: Energy supplement
Normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy supplement (E) = 1171 kJ + 12 mg iron
Study: 10902990
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement (M) = 12 mg iron + 209 kJ
Study: 26933849
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles
Study: 26933849
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles
Study: 26933849
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients not receiving bevacizumab
Study: 26933849
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients not receiving bevacizumab
Study: 26933849
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients receiving bevacizumab
Study: 26933849
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients receiving bevacizumab
Study: 25637379
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel
Study: 18405787
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/d, n=131)
Study: 18405787
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus diuretics
Study: 15660392
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (180 microg once weekly for 48 weeks)
Study: 7017171
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cinoxacin
Study: 7017171
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g nalidixic acid 4 times daily
Study: 31104069
Drug: Thrombomodulin (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombomodulin (0.06 mg/kg/d, maximum 6 mg/d) administered as an intravenous bolus or a 15-minute infusion once daily for 6 days (n = 395)
Study: 19439041
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue factor pathway inhibitor (rTFPI)
Study: 17319797
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg etomoxir
Study: 17319797
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg etomoxir
Study: 6712870
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg daily)
Study: 2577460
Drug: Slow-release oxprenolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oxprenolol (160 mg)
Study: 769697
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% solution or cream formulation
Study: 30795492
Drug: Risperidone adjunct
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone adjunct therapy for 0 weeks
Study: 20091317
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Study: 20091317
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Study: 2653395
Drug: Dextropropoxyphene 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene 180 mg and Paracetamol 1.95 g daily (D&P)
Study: 9040545
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (60 mg)
Study: 8424280
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg.kg‐1 i.v.)
Study: 8424280
Drug: Flunitrazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.03 mg.kg‐1 i.v.)
Study: 26826533
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment for 6 weeks
Study: 11999466
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg once daily (o.d.)
Study: 10411249
Drug: Oxygenator coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygenator coated with albumin in the priming solution
Study: 7547213
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg i.v. 30 min after cisplatin or 16 mg orally at the end of cisplatin infusion)
Study: 7547213
Drug: Buspirone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later)
Study: 1372924
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume paracentesis (LVP) and infusion of low molecular weight dextran (n = 20)
Study: 1372924
Drug: Aldactone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldactone 400 mg/day and furosemide 80 mg/day (n = 20)
Study: 9051202
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg)
Study: 11427639
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg)
Study: 9051202
Drug: Beta-carotene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (15 mg)
Study: 7581831
Drug: Combined supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplement (vitamin E, vitamin C, beta-carotene)
Study: 12894131
Drug: Alefacept (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (12 weekly intramuscular or intravenous injections)
Study: 26826274
Drug: Sequential media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential media (Quinn's Advantage Cleavage Medium followed by Blast Assist)
Study: 19523617
Drug: Sequential media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential media
Study: 25532586
Drug: Low-dose Saccharum
Normalized name: Acer saccharum pollen
DrugBank: Acer saccharum pollen (DB10369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose Saccharum iron (200 mg/dose, once a week for 5 weeks, total 1000 mg)
Study: 16650135
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 300 mg daily
Study: 6322906
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than 20 days treatment with sodium stibogluconate if necessary
Study: 6322906
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than 20 days treatment with sodium stibogluconate
Study: 17890954
Drug: Ultrahigh-dose streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrahigh-dose streptokinase (UH-SK n = 8)
Study: 14981602
Drug: Continuous venovenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venovenous hemofiltration (CVVH) with an ultrafiltration rate of 1 L/h
Study: 14981602
Drug: Continuous venovenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venovenous hemofiltration (CVVH) with an ultrafiltration rate of 2.5 L/h
Study: 14981602
Drug: Continuous venovenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venovenous hemodialysis (CVVHD) with a dialysate flow rate of 1 L/h
Study: 11782981
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with tissue plasminogen activator
Study: 27920119
Drug: Telephone coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone coaching by a family physician (twice a month)
Study: 25216712
Drug: Linseed oil
Normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed oil (α-linolenic acid; 7 g ALA/day)
Study: 25216712
Drug: Echium oil
Normalized name: Echium plantagineum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echium oil (stearidonic acid; 2 g SDA/day)
Study: 23431993
Drug: 25‐mg meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐mg meperidine
Study: 22080314
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 × 5 g Cr monohydrate per day)
Study: 22080314
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (4 × 5 g maltodextrin per day)
Study: 9402175
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of chemotherapy cycles > 6
Study: 30541474
Drug: Yoga (60-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (60-min sessions, 2x weekly for 10 weeks)
Study: 30541474
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education (90-min sessions, weekly for 10 weeks)
Study: 27383312
Drug: Organic melon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic melon (250 g per day for 15 days)
Study: 27383312
Drug: Market melon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Market melon (250 g per day for 15 days)
Study: 20051299
Drug: Sitagliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin plus G-CSF
Study: 16230562
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (5-ALA) pretreatment followed by intense pulsed light (IPL) treatment
Study: 16230562
Drug: IPL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL treatment alone
Study: 11851783
Drug: Nurse-administered 'side-effect'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered 'side-effect' checklists
Study: 2253903
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml radiolabelled beef consommé with 60 g margarine
Study: 2253903
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml radiolabelled beef consommé without margarine
Study: 21828142
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily
Study: 12783373
Drug: IFN up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN up to 5 MU/m(2)/d with cytarabine (Ara‐C) 20 mg/m(2)/d for 10 days every month
Study: 28829155
Drug: Ashwagandha root
Normalized name: ashwagandha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha root extract (600 mg daily)
Study: 27348483
Drug: Ledipasvir/sofosbuvir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/sofosbuvir plus GS-9669 500 mg for 8 weeks
Study: 25102686
Drug: Zaizaoshengxue tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaizaoshengxue tablets
Study: 15786529
Drug: Sucralfate 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1,000 mg thrice daily
Study: 15786529
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 10 mg thrice daily
Study: 12088306
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 mg/kg, twice daily
Study: 12088306
Drug: Methylphenidate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.5 mg/kg, twice daily